Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14404MR)

This product GTTS-WQ14404MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14404MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15349MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ11032MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ11692MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ12852MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ15843MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ11025MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ4544MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ761MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AB0024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW